Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. siroco

SIROCO SIGNED

Sparing gene therapy for Inherited ROd COne dystrophies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SIROCO project word cloud

Explore the words cloud of the SIROCO project. It provides you a very rough idea of what is the project "SIROCO" about.

dysfunction    finalize    primarily    licenses    therapy    siroco    diffuse    ophthalmology    agreements    mutations    pathology    scientific    therapeutic    progressive    board    ip    retina    corrective    option    treating    first    sahel    disease    retinitis    solution    efficacy    secured    renamed    photoreceptor    forms    models    advisory    patents    single    clinical    vision    supporting    cone    causes    2004    injection    world    remaining    protection    neurotrophic    rare    exclusive    raised    treatment    diseases    instrument    many    sme    group    potentially    treat    team    cones    saving    believe    retinal    evolution    money    rp    almost    innovative    leads    injected    lasting    photoreceptors    65    accessible    disorders    rdcvf    tomorrow    genetic    repair    dry    subsequent    pursue    mice    million    inherited    leveillard    validation    rod    amd    degenerative    young    proof    gene    small    stop    adults    patients    degeneration    blindness    stopped    people    pigmentosa    unnecessary    sparingvision   

Project "SIROCO" data sheet

The following table provides information about the project.

Coordinator		 SPARINGVISION 

Organization address
address: 55 RUE DE LYON
city: PARIS
postcode: 75012
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 3˙529˙593 €
 EC max contribution 2˙470˙715 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SPARINGVISION FR (PARIS) coordinator 2˙470˙715.00

Map

 Project objective

Many believe that corrective ophthalmology gene therapy is the future for rare diseases such as retinitis pigmentosa (RP), a rare, inherited retinal disorders characterized by diffuse progressive dysfunction of primarily rod photoreceptors, with subsequent degeneration of cone photoreceptors. This degenerative disease causes blindness to young people and adults. But with this kind of therapy only treating 1 out of 65 mutations of the pathology, it means a small group of patents can be targeted. So, what do the remaining 2 million people have as on option? SparingVision have developed an innovative treatment that can stop the evolution of this blindness and we call it RdCVF. The first vision saving treatment of its kind. What makes it different is that in 2004, J Sahel and T Leveillard identified that in RP, the main factor that leads to blindness is a loss of RdCVF with is a neurotrophic factor for the cones (photoreceptor). This means that by a single injection under the retina SparingVision’ product can treat all the genetic forms of RP, potentially treat patients with dry AMD, and provide patients with long lasting efficacy. In SparingVision’ proof of concept the product was injected to mice models provided almost immediate protection and repair to the cones and the evolution to blindness is stopped. Behind this product is a very strong team, a world renamed scientific advisory board. The product development has been secured with strong IP, exclusive licenses agreements and pursue R&D with research collaboration agreements and raised money. So, tomorrow with the help of SME INSTRUMENT supporting the project SIROCO, SparingVision will be able to finalize the next steps of the clinical validation of an unique therapeutic approach and make the product finally accessible and being the solution to stop unnecessary blindness and other degenerative conditions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIROCO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIROCO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More